BlackRock Throgmorton Trust Investment companies | Update | 22 November 2023 Growth in all things BlackRock Throgmorton Trust’s (THRG’s) continues to demonstrate its commitment to UK quality-growth small-and-mid-caps that has long characterised the trust, even in the face of apparent headwinds. While the UK small-and-mid-cap sector has been somewhat out of favour recently, the stock-specific […]
Investment trust insider on RTW Biotech – James Carthew: RTW Biotech will succeed with or without Arix I was singing the praises of capital markets days last week. Last Tuesday, I managed to get along to one held by RTW Biotech Opportunities (RTW). The day was planned some time ago, but the timing was great […]
Baillie Gifford European Growth (BGEU) has published its annual results for the year ended 30 September 2023, during which it provided NAV and share price total returns of 8.3% and 8.6% respectively, but these were significantly behind its benchmark, the FTSE Europe ex UK Index, which it says returned 20.5% (all figures in sterling terms). […]
European Opportunities Trust Investment companies | Initiation | 1 November 2023 ‘Special’ growth companies With its strong focus on growth, European Opportunities Trust (EOT) has faced significant headwinds during the last couple of years as, in the face of higher inflation and interest rates, investors have favoured more value and defensive exposures over growth stocks. Inflation […]
European Opportunities Trust Investment companies | Initiation | 1 November 2023 ‘Special’ growth companies With its strong focus on growth, European Opportunities Trust (EOT) has faced significant headwinds during the last couple of years. Inflation now seems to be coming under control, but with growing signs of a recession in Europe, sentiment is poor. Consequently, valuations […]
European Opportunities Trust Investment companies | Initiation | 1 November 2023 ‘Special’ growth companies With its strong focus on growth, European Opportunities Trust (EOT) has faced significant headwinds during the last couple of years. Inflation now seems to be retreating, but with growing signs of a recession in Europe, sentiment appears to be poor. Valuations of […]
RTW Biotech Opportunities (RTW) has announced that it will acquire Arix Bioscience. The transaction is expected to deliver RTW with an expected pro-forma net asset value of approximately $550 million, an increase of 63% The deal will enhance RTW’s profile, provide increased liquidity potential, a more efficient cost base, and a re-rating opportunity. Arix shareholders […]
Investment trust insider on biotechs – James Carthew: I’m confident my biotech casualties will recover A couple of my more disappointing investments sit in the biotech sector. I wrote about Biotech Growth (BIOG) in July last year. The investment trust had been through a rough patch, but fund manager Geoffrey Hsu was optimistic that things […]
International Biotech (IBT) announced its half-yearly report for the year ended 28 Feb 2023. The company’s share price was up 8.0% over the six month period, well ahead of the Nasdaq Biotechnology Index (NBI), which had a total return of 1.8%. The company’s Net Asset Value total return over the period was 6.1%. Over three […]
RTW Venture Fund (RTW) announced annual results for the year ended December 31 2022. NAV fell 10.2%, while shares were down -32% underperforming both of the company’s benchmarks with the Russell 2000 Biotech and Nasdaq Biotech indices down -31.3% and -10.9% respectively. The company’s discount fell to as low as 37% for the year although […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
